ZXDB Inhibitors
ZXDB inhibitors represent a class of chemical compounds that specifically target the ZXDB protein, a crucial element in a variety of biological systems due to its involvement in cellular regulation and transcriptional control. ZXDB is known to function as a transcriptional regulator, influencing gene expression and cellular signaling pathways. Compounds classified as ZXDB inhibitors act by binding to the active sites of this protein, altering its conformation and preventing its usual biological activity. The structural diversity of these inhibitors often includes small molecules featuring heterocyclic cores, which are functionalized to enhance specificity for ZXDB. The selectivity of these inhibitors is key, as they aim to block the protein's activity without impacting other proteins within the cell, making their development a challenging but scientifically significant pursuit.
The mechanisms of ZXDB inhibition vary depending on the structural attributes of the inhibitor and the molecular features of the binding site. Many of these compounds rely on hydrophobic interactions and hydrogen bonding to establish a strong interaction with the ZXDB protein. Additionally, some inhibitors may engage in covalent bonding with certain amino acids within the active site, leading to irreversible inhibition. Understanding the physicochemical properties of ZXDB inhibitors, such as their solubility, molecular weight, and lipophilicity, is crucial for predicting their behavior in complex biological environments. Extensive research is devoted to elucidating the binding dynamics between ZXDB and its inhibitors, which often involves computational modeling, crystallography, and biophysical techniques to characterize the precise interactions at the molecular level.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This cytidine analog could potentially disrupt the methylation pattern of the ZXDB gene promoter. Demethylation may lead to the unwarranted expression of ZXDB, but it could also sensitize the gene to downregulation by transcription factors that are otherwise impeded by methyl groups. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
By inhibiting histone deacetylases, Trichostatin A could increase acetylation levels of histones associated with the ZXDB gene, potentially allowing for tighter control of the gene's expression and enabling a decrease in ZXDB mRNA synthesis through a condensed chromatin state. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
As a histone deacetylase inhibitor, Suberoylanilide Hydroxamic Acid may promote the accumulation of acetylated histones in the chromatin surrounding the ZXDB gene. This alteration could lead to a decrease in the transcriptional activity of ZXDB by enabling a more restrictive chromatin configuration, thereby hindering the access of transcriptional machinery. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
5-Aza-2′-Deoxycytidine could induce hypomethylation of CpG islands within the ZXDB gene promoter. The consequent reduction in methylation might decrease the stability of transcriptional repression complexes at the ZXDB locus, leading to a potential decrease in gene expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
By binding to GC-rich sequences, Mithramycin A may obstruct the binding sites for specific transcription factors on the ZXDB gene, leading to a possible decrease in the initiation and elongation phases of ZXDB mRNA synthesis. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D could intercalate into DNA at the transcription initiation complex of the ZXDB gene, thereby physically obstructing the RNA polymerase enzyme and leading to a cessation of the transcription process of ZXDB. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid might alter the expression of ZXDB by binding to retinoic acid receptors that interact with the ZXDB gene promoter region. This binding could result in altered promoter accessibility, potentially decreasing the transcription of ZXDB by denying necessary transcription factor binding. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Through the inhibition of the mTOR pathway, Rapamycin might indirectly downregulate the expression of ZXDB by decreasing the overall rate of protein synthesis, which includes transcriptional regulators of the ZXDB gene. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
This inhibitor of phosphoinositide 3-kinases could disrupt downstream signaling pathways that are crucial for the maintenance of normal transcription levels of ZXDB, possibly leading to a reduction in its gene expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
As an inhibitor of c-Jun N-terminal kinase (JNK), SP600125 might disrupt the activity of transcription factors that are phosphorylated by JNK and are essential for the normal expression of ZXDB, potentially leading to a decrease in the transcriptional activity of the gene. | ||||||